JP2003516959A - プラバスタチンナトリウムの新規フォーム - Google Patents

プラバスタチンナトリウムの新規フォーム

Info

Publication number
JP2003516959A
JP2003516959A JP2001544662A JP2001544662A JP2003516959A JP 2003516959 A JP2003516959 A JP 2003516959A JP 2001544662 A JP2001544662 A JP 2001544662A JP 2001544662 A JP2001544662 A JP 2001544662A JP 2003516959 A JP2003516959 A JP 2003516959A
Authority
JP
Japan
Prior art keywords
pravastatin sodium
solution
pravastatin
crystalline
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001544662A
Other languages
English (en)
Japanese (ja)
Inventor
ケリ，ビルモシュ
サボー，チャバ
ナジューネ アルバイ，エディット
アロニメ，ユディト
Original Assignee
ビオガル ジョジセルジャール アール テー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26866349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2003516959(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ビオガル ジョジセルジャール アール テー． filed Critical ビオガル ジョジセルジャール アール テー．
Publication of JP2003516959A publication Critical patent/JP2003516959A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001544662A 1999-12-14 2000-12-14 プラバスタチンナトリウムの新規フォーム Pending JP2003516959A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17068599P 1999-12-14 1999-12-14
US60/170,685 1999-12-14
US19064900P 2000-03-20 2000-03-20
US60/190,649 2000-03-20
PCT/US2000/033867 WO2001043723A1 (en) 1999-12-14 2000-12-14 Novel forms of pravastatin sodium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004349020A Division JP2005120105A (ja) 1999-12-14 2004-12-01 プラバスタチンナトリウムの新規フォーム

Publications (1)

Publication Number Publication Date
JP2003516959A true JP2003516959A (ja) 2003-05-20

Family

ID=26866349

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001544662A Pending JP2003516959A (ja) 1999-12-14 2000-12-14 プラバスタチンナトリウムの新規フォーム
JP2004349020A Pending JP2005120105A (ja) 1999-12-14 2004-12-01 プラバスタチンナトリウムの新規フォーム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004349020A Pending JP2005120105A (ja) 1999-12-14 2004-12-01 プラバスタチンナトリウムの新規フォーム

Country Status (15)

Country Link
US (3) US7001919B2 (enExample)
EP (1) EP1242051A4 (enExample)
JP (2) JP2003516959A (enExample)
KR (1) KR20020062340A (enExample)
CN (1) CN1434702A (enExample)
AU (1) AU779306B2 (enExample)
CA (1) CA2394200C (enExample)
CZ (1) CZ20021998A3 (enExample)
HK (1) HK1049441A1 (enExample)
HU (1) HUP0204005A3 (enExample)
IL (1) IL150187A0 (enExample)
PL (1) PL364929A1 (enExample)
SK (1) SK8312002A3 (enExample)
WO (1) WO2001043723A1 (enExample)
YU (1) YU45202A (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1049441A1 (zh) * 1999-12-14 2003-05-16 Biogal Gyogyszergyar Rt 普伐他丁钠的崭新形式
ATE374028T1 (de) * 2001-03-27 2007-10-15 Dainippon Sumitomo Pharma Co Kristallines isoxazol-derivat und medizinisches präparat daraus
EP1737449A1 (en) * 2004-03-01 2007-01-03 LEK Pharmaceuticals D.D. Pharmaceutical composition
KR20070038553A (ko) 2004-08-06 2007-04-10 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 스타틴 약제학적 조성물 및 관련된 치료방법
CN101115706A (zh) * 2005-02-09 2008-01-30 特瓦药厂私人有限公司 制备普伐他汀钠的方法
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
CN101648867B (zh) * 2009-09-04 2012-07-11 天津大学 一种普伐他汀钠晶型及其制备方法和应用
EP2343054A1 (en) 2010-01-04 2011-07-13 LEK Pharmaceuticals d.d. Pellets and microparticles of pravastatin sodium and a process of making them
WO2012085191A1 (en) 2010-12-23 2012-06-28 Dsm Sinochem Pharmaceuticals Netherlands B.V. Crystalline form of pravastatine and process for the preparation thereof
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CN105949062B (zh) * 2016-06-24 2017-06-13 广东蓝宝制药有限公司 一种规模化制备普伐他汀钠d型晶体的工艺
CN111018714B (zh) * 2019-12-27 2020-09-04 广东蓝宝制药有限公司 一种获得高纯a晶型普伐他汀钠的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
ATE69602T1 (de) 1985-09-13 1991-12-15 Sankyo Co Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4857522A (en) 1988-03-21 1989-08-15 E. R. Squibb & Sons, Inc. Derivatives of pravastatin for inhibiting cholesterol biosynthesis
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5099035A (en) * 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
NZ250609A (en) 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
SI9300303A (en) 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
IL112639A0 (en) 1994-03-11 1995-05-26 Bristol Myers Squibb Co A pharmaceutical composition containing pravastin
US5942423A (en) 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
US5616595A (en) 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
AU6726398A (en) 1997-02-20 1998-09-09 Gist-Brocades B.V. Nitrogen feed in statin fermentation
KR100210482B1 (ko) 1997-04-10 1999-07-15 김종인 스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
AU9264598A (en) 1997-08-22 1999-03-16 Gist-Brocades B.V. Statin production by fermentation
SI9800046A (sl) 1998-02-18 1999-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
SI20072A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
SI20305A (sl) 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
AU2161000A (en) * 1998-12-07 2000-06-26 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
US6682913B1 (en) 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
SK10932001A3 (sk) 1999-02-03 2002-06-04 Institute For Drug Research Ltd. Mikrobiálny spôsob výroby pravastatínu
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
WO2001039768A1 (en) 1999-11-30 2001-06-07 Biogal Gyogyszergyar Rt Process for recovering statin compounds from a fermentation broth
HK1049441A1 (zh) * 1999-12-14 2003-05-16 Biogal Gyogyszergyar Rt 普伐他丁钠的崭新形式
HRP20030347A2 (en) 2000-10-05 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
DE10209305A1 (de) 2001-04-30 2002-10-31 Basf Ag Thermische Spaltung von Allophanaten

Also Published As

Publication number Publication date
EP1242051A1 (en) 2002-09-25
US20050288370A1 (en) 2005-12-29
JP2005120105A (ja) 2005-05-12
HUP0204005A3 (en) 2003-05-28
WO2001043723A1 (en) 2001-06-21
KR20020062340A (ko) 2002-07-25
CZ20021998A3 (cs) 2003-02-12
US7001919B2 (en) 2006-02-21
US20010041809A1 (en) 2001-11-15
PL364929A1 (en) 2004-12-27
IL150187A0 (en) 2002-12-01
US20070197633A1 (en) 2007-08-23
SK8312002A3 (en) 2003-05-02
EP1242051A4 (en) 2004-05-12
AU2098701A (en) 2001-06-25
YU45202A (sh) 2005-11-28
CA2394200C (en) 2006-10-03
HK1049441A1 (zh) 2003-05-16
HUP0204005A2 (hu) 2003-03-28
CA2394200A1 (en) 2001-06-21
CN1434702A (zh) 2003-08-06
AU779306B2 (en) 2005-01-13
US7262218B2 (en) 2007-08-28

Similar Documents

Publication Publication Date Title
US20070197633A1 (en) Novel forms of pravastatin sodium
JP7086118B2 (ja) Ｌ－オルニチンフェニルアセテートおよびその製造方法
JP2020183408A (ja) ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
KR20220017932A (ko) 타파미디스 및 그 염의 고상형
JP2009149654A (ja) 多形性化合物
US20030073648A1 (en) Crystaline clindamycin free base
CN116987069B (zh) 呋喹替尼的共晶、其制备方法、组合物和用途
JP2025074350A (ja) Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
WO2015176591A1 (zh) 贝曲西班盐及其制备方法和用途
KR20030081424A (ko) 피리미딘 뉴클레오시드 유도체의 결정
CN105315266B (zh) 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型
CN115772166B (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
EP1523978A2 (en) Crystalline forms of pravastatin sodium
CA2551203A1 (en) Novel forms of pravastatin sodium
KR102150825B1 (ko) 새로운 sglt-2 억제제의 신규한 공결정
KR20230087557A (ko) 로레시비빈트의 고상형
HK40106546B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
CN119263973A (zh) 蒽贝素的新晶型及其制备方法和用途

Legal Events

Date Code Title Description
A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20040324

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20040526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050215